Medicare Enrolled
Dr. Sreedevi Daggubati, MD
Hematology & Oncology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Daggubati from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Daggubati? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Daggubati
Dr. Sreedevi Daggubati is a hematology & oncology in San Antonio, TX, with 20 years in practice. Based on federal Medicare data, Dr. Daggubati performed 254,565 Medicare services across 7,984 unique beneficiaries.
Between the years covered by Open Payments, Dr. Daggubati received a total of $6,820 from 41 pharmaceutical and/or device companies across 285 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Daggubati is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 1% volume in TX$ $6,820 industry payments
Medicare Practice Summary
Medicare Utilization ↗254,565
Medicare services
Top 1% in TX for hematology & oncology
7,984
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~12,728 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Azacitidine chemotherapy injection | 56,256 | $0 | $13 |
| Anti-nausea injection (fosaprepitant) | 31,500 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 30,100 | $43 | $137 |
| Iron sucrose injection (Venofer) | 22,000 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 16,910 | $2 | $20 |
| Immune globulin infusion (Octagam) | 15,760 | $33 | $234 |
| Iron infusion (Feraheme) | 13,770 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 9,280 | $0 | $3 |
| Paclitaxel chemotherapy injection | 8,730 | $0 | $8 |
| Denosumab injection (Prolia/Xgeva) | 5,640 | $18 | $66 |
| Dexamethasone injection (steroid) | 5,528 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,990 | $22 | $181 |
| Blood draw (venipuncture) | 2,731 | $8 | $20 |
| Complete blood count (CBC) with differential | 2,628 | $8 | $36 |
| Comprehensive metabolic blood panel | 2,535 | $10 | $64 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,340 | $1 | $114 |
| Injection, atropine sulfate, 0.01 mg | 2,280 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,790 | $0 | $24 |
| Office visit, established patient (30-39 min) | 1,742 | $90 | $368 |
| Flow cytometry, additional marker | 1,708 | $18 | $180 |
| Injection, fulvestrant, 25 mg | 1,360 | $8 | $244 |
| Immunoglobulin level test | 1,032 | $9 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 1,011 | $22 | $157 |
| Epoetin alfa injection (Retacrit) for anemia | 1,010 | $6 | $28 |
| Injection, fluorouracil, 500 mg | 994 | $2 | $13 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 775 | $53 | $211 |
| Injection, zoledronic acid, 1 mg | 762 | $6 | $431 |
| Administration of chemotherapy into vein, 1 hour or less | 732 | $97 | $707 |
| Injection, carboplatin, 50 mg | 702 | $2 | $300 |
| Carcinoembryonic antigen (cea) protein level | 619 | $19 | $99 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 564 | $85 | $1,348 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 458 | $47 | $313 |
| Cyclophosphamide, 100 mg | 453 | $16 | $203 |
| Drug injection, under skin or into muscle | 415 | $10 | $96 |
| Ferritin level test (iron stores) | 397 | $13 | $60 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 390 | $20 | $128 |
| Iron level test | 378 | $6 | $27 |
| Iron binding capacity test | 378 | $9 | $35 |
| Measurement of immunoglobulin light chains | 376 | $17 | $60 |
| Office visit, established patient (20-29 min) | 353 | $59 | $250 |
| Lactate dehydrogenase (enzyme) level | 302 | $6 | $31 |
| Administration of additional new drug or substance into vein, 1 hour or less | 300 | $48 | $344 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 297 | $3 | $373 |
| Microscopic examination for white blood cells with manual cell count | 268 | $4 | $22 |
| Complete blood count (CBC), automated | 268 | $6 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 242 | $15 | $100 |
| Administration of chemotherapy into vein, each additional hour | 234 | $21 | $161 |
| Reticulated (young) platelet measurement | 198 | $35 | $143 |
| Irrigation of implanted venous access drug delivery device | 163 | $18 | $114 |
| Injection, diphenhydramine hcl, up to 50 mg | 159 | $1 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 146 | $25 | $145 |
| Vitamin B-12 level test | 115 | $15 | $76 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 115 | $123 | $500 |
| Infusion, normal saline solution , 1000 cc | 115 | $2 | $19 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 114 | $272 | $2,762 |
| Injection of additional new drug or substance into vein | 113 | $12 | $108 |
| Folic acid level test | 112 | $14 | $73 |
| New patient office visit (45-59 min) | 101 | $120 | $565 |
| Ct scan of chest with contrast | 97 | $44 | $821 |
| Thyroid stimulating hormone (TSH) test | 96 | $16 | $80 |
| CT scan of abdomen and pelvis with contrast | 94 | $159 | $1,067 |
| Administration of additional new drug or substance into vein using push technique | 90 | $41 | $289 |
| Beta-2 microglobulin (protein) level | 82 | $16 | $96 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 78 | $20 | $128 |
| PSA test (prostate cancer screening) | 76 | $18 | $94 |
| Uric acid level test | 70 | $4 | $25 |
| Flow cytometry technique for dna or cell analysis, first marker | 68 | $56 | $298 |
| Infusion into a vein for hydration, 31-60 minutes | 67 | $24 | $256 |
| Drawing of blood for a medical problem | 66 | $59 | $264 |
| Unclassified drugs | 66 | $1 | $8 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 60 | $20 | $128 |
| Red blood count automated, with additional calculations | 59 | $5 | $26 |
| Haptoglobin (serum protein) level | 49 | $12 | $66 |
| Application of on-body injector for under skin injection | 47 | $14 | $96 |
| Alpha-fetoprotein (afp) level, serum | 43 | $16 | $102 |
| Sed rate test (inflammation marker) | 42 | $3 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 42 | $15 | $94 |
| New patient office visit, complex (60-74 min) | 42 | $168 | $709 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 41 | $178 | $700 |
| Injection of drug or substance into vein | 37 | $27 | $247 |
| C-reactive protein test (inflammation marker) | 36 | $5 | $33 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 35 | $90 | $657 |
| Urinalysis with microscopic exam | 33 | $3 | $28 |
| Magnesium level test | 33 | $7 | $29 |
| CT scan of chest, without contrast | 32 | $36 | $686 |
| Protein measurement, serum | 31 | $11 | $99 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 27 | $1,102 | $4,802 |
| Immunologic analysis technique on serum (immunofixation) | 27 | $22 | $160 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 27 | $4 | $25 |
| Infusion into a vein for hydration, each additional hour | 24 | $10 | $75 |
| Coagulation function measurement, d-dimer; quantitative | 23 | $10 | $129 |
| Ct scan of abdomen and pelvis without contrast | 19 | $76 | $560 |
| Prothrombin time test (blood clotting) | 19 | $4 | $30 |
| Office visit, established patient, complex (40-54 min) | 17 | $133 | $496 |
| Ct scan of soft tissue of neck with contrast | 16 | $54 | $658 |
| Stool analysis for blood to screen for colon tumors | 15 | $4 | $24 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.4% high complexity
80.2% medium
7.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,820
Total received (2018-2024)
Avg $974/year across 7 years
Top 38% in TX for hematology & oncology
41
Companies
285
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,341 (78.3%)
Other
Charitable contributions, space rental, and other categories
$1,080 (15.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$398 (5.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,807
2023$162
2022$401
2021$490
2020$477
2019$1,753
2018$1,729
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,486
E.R. Squibb & Sons, L.L.C.
$1,027
Janssen Biotech, Inc.
$572
Eisai Inc.
$419
Merck Sharp & Dohme Corporation
$354
PFIZER INC.
$321
Genentech USA, Inc.
$306
Amgen Inc.
$258
Alexion Pharmaceuticals, Inc.
$205
Rigel Pharmaceuticals, Inc.
$184
Myriad Genetic Laboratories, Inc.
$182
EISAI INC.
$168
Genmab U.S., Inc.
$125
Lilly USA, LLC
$125
Agios Pharmaceuticals, Inc.
$122
SEAGEN INC.
$100
Celgene Corporation
$90
Regeneron Healthcare Solutions, Inc.
$82
GENZYME CORPORATION
$82
Janssen Pharmaceuticals, Inc
$81
GlaxoSmithKline, LLC.
$67
Astellas Pharma US Inc
$47
Gilead Sciences, Inc.
$41
Puma Biotechnology, Inc.
$35
EMD Serono, Inc.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$33
Dendreon Pharmaceuticals LLC
$28
Array BioPharma Inc.
$28
Dova Pharmaceuticals
$24
PUMA BIOTECHNOLOGY, INC.
$23
Bayer HealthCare Pharmaceuticals Inc.
$21
AbbVie, Inc.
$21
Pharmacyclics LLC, An AbbVie Company
$17
AstraZeneca Pharmaceuticals LP
$17
AMAG Pharmaceuticals, Inc.
$16
Teva Pharmaceuticals USA, Inc.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Seagen Inc.
$13
TerSera Therapeutics LLC
$13
Seattle Genetics, Inc.
$12
Incyte Corporation
$11
Top 3 companies account for 45.2% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · Alecensa · Avastin · BENDEKA · BLENREP · BOSULIF · Bavencio · Braftovi · CHANTIX · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMEND · EMPLICITI · ERLEADA · Epkinly · Erleada · FERAHEME · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · Lenvima · Lunsumio · MEKINIST · MYLOTARG · MYRISK · NERLYNX · Neulasta · OPDIVO · PADCEV · PIQRAY · PRECISETUMOR · PROMACTA · PROVENGE · Perjeta · Pomalyst · REBLOZYL · RYDAPT · Revlimid · SOLIRIS · SPRYCEL · SUTENT · Stivarga · TASIGNA · TECENTRIQ · TIBSOVO · Tavalisse · ULTOMIRIS · VOTRIENT · Vectibix · Venclexta · XALKORI · XARELTO · XTANDI · ZOLADEX · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (78%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
UNIVERSITY HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Daggubati is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Daggubati experienced with azacitidine chemotherapy injection?
Based on Medicare claims data, Dr. Daggubati performed 56,256 azacitidine chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Daggubati receive payments from pharmaceutical companies?
Yes. Dr. Daggubati received a total of $6,820 from 41 companies across 285 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Daggubati's costs compare to other hematology & oncologys in San Antonio?
Dr. Daggubati's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Daggubati) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in San Antonio
Browse hematology & oncologys in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology